Rosen Law Firm Encourages Immutep Ltd. Investors to Inquire About Securities Class Action Investigation - IMMP

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Immutep Ltd. due to allegations of materially misleading business information issued by the company [1]. Group 1: Class Action Details - Investors who purchased Immutep securities may be entitled to compensation through a contingency fee arrangement, with no out-of-pocket costs [2]. - The law firm is preparing a class action to seek recovery of investor losses [2]. Group 2: Recent Company Developments - On March 13, 2026, Immutep announced the discontinuation of the TACTI-004 Phase III study for eftilagimod alfa in non-small cell lung cancer, following a recommendation from the Independent Data Monitoring Committee based on a futility analysis [3]. - Following this announcement, Immutep's American Depositary Receipt price fell by $2.28, or 82.6%, closing at $0.48 per ADR on the same day [3]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting its own achievements in recovering hundreds of millions for investors [4]. - The firm has been recognized for its performance in securities class action settlements, including being ranked No. 1 by ISS Securities Class Action Services in 2017 and securing over $438 million for investors in 2019 [4].